Aurora Cannabis Inc. (ACB) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 50.2 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 58/100 (D+) score, ACB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.04) or 200D SMA ($3.54) invalidates the momentum regime and cuts Target Base ($4.08) toward Bear Floor ($3.18).
Aurora Cannabis Inc. (ACB) slipped 0.00% to $4.08, trading at 40% of its 52-week range ($2.56 – $6.36). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
China and Switzerland just agreed to scrap tariffs on most traded goods, including Swiss medical devices, which puts a global spotlight on healthcare products and technology. That kind of cross border opening can sharpen
If Green Thumb's high cash flow persists, regulatory progress could fuel a massive rally for this profitable marijuana stock.
EDMONTON, Alberta, October 29, 2026--Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor co
SNDL's Q3 sales beat expectations, but margin pressure and persistent cannabis weakness cloud its recovery. Can buybacks and U.S. expansion turn the tide?
SNDL Inc. posted record free cash flow but faces near-term earnings pressure from restructuring and product cuts. Click for this earnings update of SNDL stock.
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today issued the following statement in response to the Alberta Securities Comm
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today shared that the application made by Curaleaf Holdings, Inc. ("Curaleaf") (TSX:
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today shared that the application made by Curaleaf Holdings, Inc.
A market sell-off spread beyond tech as oil prices surged and AI concerns grew. MarketBeat analysts recap the week's top stories on earnings, from Halliburton to Meta Platforms and General Motors.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Aurora Cannabis Inc. (ACB) ranks #232 by composite RQD confidence (58/100, grade D+) and #544 by equity capitalization ($252.8M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with ACB at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACB
ACTIVE
Aurora Cannabis Inc. | D+ | 58/100 | — | — | — | 0.00% | $252.8M | Benchmark Subject |
| USNA USANA Health Sciences Inc. | C- | 61/100 | 24.6x | 78.3% | 7.9% | -1.91% | $265.0M | /usna-vs-acb → |
| CGC Canopy Growth Corporation | D | 51/100 | — | — | — | +0.46% | $285.6M | /cgc-vs-acb → |
| SNDL SNDL Inc. | C- | 61/100 | — | — | — | +0.78% | $316.3M | /sndl-vs-acb → |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | E | 25/100 | — | 42.3% | -9.2% | +1.33% | $200.6M | /glas-vs-acb → |
Aurora Cannabis Inc. (ACB) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $252.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Aurora Cannabis Inc. (NASDAQ: ACB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $4.08 (0.00% 1D, market cap $252.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ACB ranks #232 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), ACB carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a C- grade (61/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and CGC (Canopy Growth Corporation) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $285.6M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
For Aurora Cannabis Inc. (ACB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #232 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
ACB last traded at $4.08 (0.00% on volume of 510,052 shares), positioning the stock +0.99% above its 50-day simple moving average ($4.04) and +15.25% above its 200-day simple moving average ($3.54). Across its 52-week range of $2.56 to $6.36, ACB sits at the 40.0% percentile with a 14-day RSI of 50.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.8% ($3.72 to $4.44).
Why ACB Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.